Harmony Biosciences Holdings (HRMY) Balance Sheet
A balance sheet shows what a company owns and owes, and shareholders' equity, at a single point in time.
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States.
Total Assets Chart for Harmony Biosciences Holdings
Harmony Biosciences Holdings (HRMY) total assets for FY2025 were USD 1.3B, a 27.3% change from FY2024. Harmony Biosciences Holdings's total assets grew from USD 89.3M in 2018 to USD 1.3B in 2025 (1324.3% over 7 years). Total assets compound annual growth rate: 5-year CAGR of 24.4%.
Total Assets (US Dollars)
R&D as % of Revenue
Compare with
Key Stats
- Market Cap
- $2.10B
- Implied Share Price
- $36.13
- Enterprise Value
- $1.91B
- Revenue (TTM)
- $959.90M
- EBITDA
- $255.99M
- Profit Margin
- 18.88%
- Trailing P/E
- 11.65
- Forward P/E
- 10.32
- Price/Book (MRQ)
- 2.42
- Price/Sales (TTM)
- 2.19
- EV/EBITDA
- 6.80
- EV/Revenue
- 1.98
- Dividend Yield
- —
- Book Value
- $17.19
- Free Cash Flow (FY2025)
- $347.89M
- Free Cash Flow Yield
- 16.53%
Snapshot as of 24th October 2026 — not point-in-time controlled, may lag the live market by a few days.